The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome

Zara Sayar¹,², Shoshana Burke¹, Prabal Mittal¹,³ and Hannah Cohen¹,³

Abstract
Limited evidence exists to guide the management of recurrent thrombosis occurring despite therapeutic anticoagulation in patients with thrombotic antiphospholipid syndrome (APS). In this case series, fondaparinux, with or without an antiplatelet agent, provided an effective and safe option in three patients with thrombotic APS, all two triple and one single positive for antiphospholipid antibodies, who had recurrent venous and/or arterial thromboembolism. Rituximab was also used in all patients. Recurrent events occurred despite therapeutic anticoagulation, including at high-intensity, with warfarin and subsequent low-molecular-weight heparin. There were no major bleeding events. Adjunctive therapies used for thrombosis included catheter-directed thrombolysis and rituximab.

Keywords
fondaparinux, recurrent thrombosis, venous thromboembolism, arterial thrombosis, antiphospholipid syndrome

Introduction
Rates of recurrent thrombosis in specific cohorts, rather than in the general population, vary. Antiphospholipid syndrome (APS) is characterised by thrombotic (venous, arterial and/or microvascular) and/or obstetric morbidity in association with persistently positive antiphospholipid antibodies (aPL; lupus anticoagulant [LA], IgG and/or IgM anti–beta-2 glycoprotein-1 [aβ2GP1] and anticardiolipin antibodies [aCL]).¹ Triple aPL-positive APS patients (i.e. who have LA, IgG and/or IgM anti–beta-2 glycoprotein-1 and anticardiolipin antibodies) are at particularly high risk for recurrent thrombosis.² Annualised recurrent thrombosis rates in patients with APS on vitamin K antagonist (VKA) were 1.3–4.0% in two prospective randomised controlled trials³,⁴ and 4.3% and 4.8% in a prospective⁵ and retrospective cohort study, respectively, the latter in triple aPL-positive patients.² In a systematic review of 728 patients with APS treated with a direct oral anticoagulant (DOAC), 119 of 246 (48.3%) were triple aPL-positive, with the approximate annualised recurrent thrombosis rate 11%.⁶ Recurrent venous and/or arterial thromboembolism while on therapeutic anticoagulation is observed in several conditions other than APS, including cancer.

If a patient develops anticoagulant-refractory thrombosis, it is important to objectively confirm this by appropriate imaging techniques. Adherence to anticoagulation should be assessed. Alternative causes of thrombosis should be considered, such as the development of heparin-induced thrombocytopenia² or malignancy⁸ such as myeloproliferative neoplasms or monoclonal gammopathy of undetermined significance (MGUS). Additional risk factors should be addressed, including the use of oestrogen-containing preparations.⁹ A review of bleeding risk factors should also be considered, with active management of any identified factors, to facilitate optimal antithrombotic treatment. Recurrent thromboses that occur due to a subtherapeutic International Normalised Ratio (INR) could be related to non-adherence or a spurious therapeutic INR due to LA effect on thromboplastin.¹⁰

The management of anticoagulant-refractory thrombosis can be challenging, and current guidelines are largely extrapolated from cancer cohorts.¹¹,¹² If further thrombotic events occur, despite the use of either high-intensity warfarin

¹Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK
²Department of Haematology, Whittington Health NHS Trust, London, UK
³Haemostasis Research Unit, Department of Haematology, University College London, London, UK

Corresponding author:
Dr Zara Sayar, Department of Haematology, University College London, 1st Floor, 51 Chenies Mews, London WC1E 6HX.
Email: zara.sayar@nhs.net
(INR target 3.5, range 3.0–4.0) or low-molecular-weight heparin (LMWH), evidence regarding further escalation of anticoagulation is limited. Fondaparinux is a synthetic analogue of heparin pentasaccharide required for antithrombin binding. It is mainly used in the treatment of heparin-induced thrombocytopenia7 and has specific anti-factor Xa activity that is seven times higher than LMWH. It is eliminated exclusively by the kidneys with an elimination half-life of 17 h,13 and therefore contraindicated in severe renal impairment.11 Two patients with APS treated with fondaparinux and mycophenolate mofetil have been reported to have favourable outcomes with no recurrent events in a 4-year follow-up period.14 This may be an option in recurrent thrombotic events with or without the addition of an antiplatelet agent.15

Here, we review fondaparinux and rituximab use in a single centre, for recurrent thrombotic events despite therapeutic warfarin and/or LMWH.

Methods

Patients receiving fondaparinux for recurrent thrombosis were identified from the complex anticoagulation clinic at University College Hospital (UCH), London. A retrospective review of the notes was performed to identify patients with thrombotic APS who had experienced breakthrough thrombosis while on anticoagulation. Data were collected on thrombotic events and their management, including the use of adjunctive therapies to manage thrombosis. Written informed consent was obtained from the patients included in this case series.

Results and discussion

Thrombotic histories and anticoagulation treatment are detailed in Table 1.

Three patients (two females, one male), median age 31 (range 28–42) years were on long-term fondaparinux. Two patients had triple aPL-positive thrombotic APS and one was single aPL-positive. Patient 1 also had a history of obstetric APS. No patients had a diagnosis of malignancy. Patients 1 and 3 were tested for monoclonal gammopathy16 and JAK2 V617F,17 neither of which were present. Patient 2 has not been tested for these.

The initial thrombotic event was venous in two patients: deep vein thrombosis (DVT) and cerebral venous sinus thrombosis. Treatment of these events was standard-intensity warfarin (INR target 2.5, range 2.0–3.0). Further thrombotic events in these patients included arterial (Patients 1 and 3) and venous only in Patient 2. One patient presented with an arterial event (middle cerebral artery [MCA] infarct), managed initially with antiplatelet treatment alone. A further contralateral MCA infarct and subsequent diagnosis of APS led to a change in antithrombotic treatment to high-intensity warfarin (INR target 3.5, range 3.0–4.0).18,19 Subsequent recurrent thrombotic events in this patient were venous.

Initial management of recurrent thrombosis included assessment of anticoagulation intensity at the time of the event and patient adherence. In all three cases, LMWH was used up to approximately 30% above standard treatment dose for further thrombotic events, prior to switching to standard therapeutic dose fondaparinux (see Figure 1). Patient 1 received split-dose high-intensity dalteparin, approximately 20% above standard treatment dose, after recurrent DVT while on warfarin as the INR was 3.4 at the time of re-thrombosis. Patient 3 received clopidogrel together with fondaparinux, split dose, as additional antithrombotic treatment. There were no subsequent thrombotic events on fondaparinux plus clopidogrel in patient 3. There were no major or clinically relevant non-major bleeding events. The median follow-up on fondaparinux was 70 (range 45–81) months.

Two patients in this case series have triple aPL-positive APS supporting that these patients are at particularly high thrombotic risk. In a retrospective study of the clinical course of 123 triple aPL-patients receiving long-term anticoagulation (mean follow-up 6.0 (±4.6) years, 36/123 (16 venous, 20 arterial) developed subsequent thromboembolism.7 The median INR at the time of these events was 2.3. Two patients experienced a recurrent arterial event after an initial venous thrombotic event (Patient 1 and 3); and the third (patient 2), a venous event after an initial arterial event. In a study on the sites of recurrent thrombosis that follows an initial event in APS patients on VKA (N = 70), arterial events were followed by arterial events, and venous events by venous in 91% (49/54).20 A further study of 147 APS patients reported rates of 93% (89/96) and 76% (69/90) of patients, respectively.21 Thus, in most cases of patients treated with VKA, arterial and venous events “bred true,” unlike in this case series.

All three APS patients received a course of rituximab (375 mg/m² × 4 weekly doses) as empirical treatment for anticoagulant-refractory thrombosis. The 16th International Congress on Antiphospholipid Antibodies Treatment Trends Task Force suggests that rituximab may have a role in the treatment of some aPL-related non-criteria manifestations and refractory catastrophic APS; and notes the paucity of evidence to inform the use of rituximab for anticoagulant-refractory thrombotic APS,18 with case reports documenting its use.22

Catheter-directed thrombolysis (CDT) was used in one patient in the acute situation in our case series with an iliofemoral DVT. In the catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis (CaVenT) randomised controlled trial that compared the short-term efficacy of CDT with standard treatment (anticoagulation and elastic compression stockings) in 103 patients, iliofemoral patency after six months was 64% in the CDT arm and 36% in the standard treatment arm.23

Our case series reports on the use of fondaparinux and rituximab for recurrent thrombosis in patients with APS; the
### Table 1. Thrombotic histories, anticoagulation treatment and additional therapeutic modalities

| Patient details: | Approximate CrCl (C&G) (ml/min) | Weight range (kg) | Underlying thrombotic diagnosis | Initial thrombosis (0 months) | 1st re-thrombosis and treatment | 2nd re-thrombosis and treatment | 3rd re-thrombosis and treatment | 4th re-thrombosis and treatment | 5th re-thrombosis and treatment |
|-----------------|---------------------------------|-------------------|---------------------------------|-------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Patient 1: 28-year-old female | 112 | 82–97 | Thrombotic APS; Triple aPL-positive: IgG aj2GPI 37.3 U/mL; IgM aj2GPI 28.4 U/mL; IgG aCL 22.1 U/mL; IgM aCL neg; TVT dilute phospholipid ratio 1.37 (NR: 0.8–1.2) | Right popliteal DVT aged 28 years, week 20 of 1st pregnancy (LMWH until 6w postpartum) Obstetric APS aged 30 years: Pre-eclampsia 28 weeks’ gestation | 40y Warfarin target 2.5, (range 2.0–3.0) APS diagnosed | 4 months Extension of DVT to left common femoral vein while INR 2.5 Warfarin target INR increased to 3.5 (range 3.0–4.0) | 12 months DVT extension within common femoral vein, also involving external iliac vein while INR 3.4 ~20% increase on standard treatment dose LMWH | 24 months Left sigmoid sinus thrombosis Acute frontal infarct following MRA ~30% increase on standard treatment dose LMWH | 36 months Segmental PE Course of rituximab Switched to fondaparinux 7.5 mg od |
| Patient details: | Approximate CrCl (C&G) (ml/min) | Weight range (kg) | Underlying thrombotic diagnosis | Initial thrombosis (0 months) | 1\textsuperscript{st} re-thrombosis and treatment | 2\textsuperscript{nd} re-thrombosis and treatment | 3\textsuperscript{rd} re-thrombosis and treatment | 4\textsuperscript{th} re-thrombosis and treatment | 5\textsuperscript{th} re-thrombosis and treatment |
|-----------------|-------------------------------|------------------|--------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Patient 2: 42-year-old male | 127 | 116–124 | Thrombotic APS: Arterial and venous thrombosis; triple aPL-positive: IgG aβ2GPI >100U/mL, IgM aβ2GPI neg, IgG aCL 49.4U/mL, IgM aCL neg\textsuperscript{a} | Left MCA infarct: Initial standard treatment with antiplatelet agents | 1 month Right MCA infarct Triple aPL-positive identified | Warfarin target INR 3.5 (range 3.0–4.0) | 21 months Right popliteal vein DVT (INR 2.6 at time of event) Continued warfarin (target INR 3.5) | 23 months Proximal extension of DVT to superficial femoral vein (INR 2.2 at time of event) Standard treatment dose LMWH | 23.5 months Segmental PEs ~20% increase on standard treatment dose LMWH | 26 months Proximal DVT extension to common femoral vein Switched to fondaparinux 5 mg bd Course of rituximab |
| Patient 3: 31-year-old female | 101 | 76–94 | Thrombotic APS: Arterial and venous thrombosis; IgG aβ2GPI 96.8U/mL\textsuperscript{b}, IgM aβ2GPI neg, IgG aCL neg, IgM aCL neg, LA negative | Cerebral venous sinus thrombosis Warfarin target INR 2.5 (range 2.0–3.0) | 5 months Cerebral venous sinus thrombosis (very erratic INRs) Standard treatment dose LMWH | 14 months Multiple anterior and posterior arterial circulation infarcts ~20% increase on standard treatment dose LMWH | IVC filter inserted Course of rituximab | 24 months Bilateral iliofemoral + IVC thrombus with renal vein thrombosis Catheter-directed thrombolysis Fondaparinux 5 mg bd and clopidogrel started |

\textsuperscript{a}Medium or high titre is defined as >40 GPL or MPL or >99th percentile, and/or a β2GPI (IgG and/or IgM) >99th percentile.\textsuperscript{1}

Abbreviations: aPL: antiphospholipid antibodies; APS: antiphospholipid syndrome; bd: twice daily; CrCl (C&G): Cockcroft and Gault creatinine clearance; DVT: deep venous thrombosis; ECT: ecarin time; IJV: internal jugular vein; INR: international normalised ratio (all venous); IVC: inferior vena cava; LMWH: low-molecular–weight heparin; m: month; MCA: middle cerebral artery; MRA: magnetic resonance angiography; neg: negative; NR: normal range; od: once daily; PE: pulmonary embolism; PICC: peripherally inserted central catheter; triple positive: presence of lupus anticoagulant, TVT: taipan venom time; IgG/IgM: anticardiolipin and anti-β2 glycoprotein I antibodies; w: weeks; y: years.
generalisability of our results to other conditions associated with recurrent thrombosis (e.g. cancer) is undefined. Anticoagulation for recurrent thrombosis can be summarised thus (Figure 1): if recurrent thrombosis occurs while on a DOAC, a switch to LMWH or to VKA should be considered. For thrombosis that occurs while on standard therapeutic dose LMWH, the dose may be escalated by 25% and 33% sequentially. For recurrent thrombosis while taking standard-intensity VKA (INR target range 2.0–3.0), the target INR may be increased to high-intensity VKA (INR target range 3.0–4.0).

**Conclusion**

In this small case series, fondaparinux provided effective and safe anticoagulation in three APS patients, who experienced recurrent arterial and/or venous thrombosis despite therapeutic anticoagulation, including at high-intensity, with warfarin and subsequent LMWH. Rituximab was used in all patients.

**Declaration of Conflicting Interests**

H Cohen reports, outside the submitted work, support to attend a scientific meeting from Bayer Healthcare; honoraria for lectures from Technoclone, and consultancy fees from UCB Biopharma paid to University College London Hospitals Charity; Roche Scientific Advisory Board. ZS, SB and PB have no conflict of interests to declare.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Informed consent**

PM gained consent from patients.

**ORCID iD**

Zara Sayar  https://orcid.org/0000-0003-2032-390X
References

1. Miyakias S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost.* 2006;4(2):295-306.

2. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. *J Thromb Haemost.* 2010;8(2):237-242.

3. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. *N Engl J Med.* 2003;349(12):1133-1138.

4. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). 1. *J Thromb Haemost.* 2005;3(5):848-853.

5. Cervera R, Khamashta MA, Shoenfeld Y, et al. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. *Ann Rheum Dis.* 2009;68(9):1428-1432.

6. Sanchez-Redondo J, Espinosa G, Delgado DV, et al. Recurrent thrombosis with direct oral anticoagulants in antiphospholipid syndrome: a systematic literature review and meta-analysis. *Clin Ther.* 2019. 41(9):1839-1862.

7. Cuker A, Arepally GM, Chong BH, et al. American society of hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. *Blood Adv.* 2018;2(22):3360-3392.

8. Kearon C, Akk EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *Chest.* 2016;149(2):315-352.

9. Martinelli I, Lensing AW, Middeldorp S, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. *Blood.* 2016;127(11):1417-1425.

10. Tripodi A, de Laat B, Wahl D, et al. Subcommittees on control of anticoagulation and lupus anticoagulant/antiphospholipid antibodies. Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: communication from the SSC of the ISTH. *J Thromb Haemost.* 2016;14(11):2304-2307.

11. Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. *J Thromb Haemost.* 2009;7(5):760-765.

12. Kearon C, Akk EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidence-based clinical practice guidelines. *Chest.* 2012; 141(2):e419S-e496S.

13. Samama M and Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). *Thromb Res.* 2003;109(1):1-11.

14. Baron B and Baron J. Four-year follow-up of two patients on maintenance therapy with fondaparinux and mycophenolate mofetil for microthrombotic antiphospholipid syndrome. *Lupus.* 2019;28(8) 10.1177/0961203319851863.

15. Cohen H, Sayar Z, Efthymiou M, et al. Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. *Lancet Haematol.* 2020;7(8):e613-e623.

16. Doyle AJ, Breen KA and Hunt BJ. Antiphospholipid syndrome with monoclonal gammopathy - a mechanism for recurrent thrombosis? *Thromb Haemost* 2021;121:1387-1390.

17. Sayar Z, Nallamilli S, Efthymiou M, et al. Coexistent antiphospholipid syndrome and myeloproliferative neoplasm. *Lupus* 2021;30(9):1502-1508.

18. Cohen H, Cuadrado MJ, Erkan D, et al. 16th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. *Lupus* 2020;29:1571-1593.

19. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. *Ann Rheum Dis.* 2019. 78(10):1296-1304.

20. Rosove MH and Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. *Ann Intern Med.* 1992;117(4):303-308.

21. Khamashta MA, Cuadrado MJ, Mucic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. *N Engl J Med.* 1995;332(15):993-997.

22. Cohen H and Isenberg DA. How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. *Blood.* 2021;137(3):299-309.

23. Enden T, Klów N, Sandvik L, et al. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. *J Thromb Haemost.* 2009; 7(8):1268-1275.